GlassScriptPhysician profile
Gino K In
NPI 1912227273
$72,944.35
in general payments reported to CMS, 2019-2025
29 companies · $10K in 2025
The $10K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $15K · 2021: $11K · 2022: $177 · 2023: $9,393 · 2024: $4,754 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,397 · Honoraria: $6,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,020 · Travel and Lodging: $3,070 · Food and Beverage: $2,519 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,396.50 |
| Honoraria | $6,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,020.00 |
| Travel and Lodging | $3,070.48 |
| Food and Beverage | $2,518.63 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23,620.42 | 2019-2025 | Welireg, Keytruda |
| Regeneron Healthcare Solutions, INC. | $17,026.02 | 2019-2025 | Libtayo |
| Genzyme Corporation | $8,840.00 | 2021 | |
| Array Biopharma INC | $7,627.41 | 2019-2025 | Braftovi, Mektovi |
| Regeneron Pharmaceuticals, INC. | $7,294.85 | 2021-2025 | Libtayo |
| Immunocore Limited | $3,977.27 | 2023-2025 | Kimmtrak |
| E.R. Squibb & Sons, L.L.C. | $2,167.22 | 2019-2024 | Opdualag |
| Aadi Bioscience, INC. | $799.02 | 2023-2024 | Fyarro |
| Incyte Corporation | $200.74 | 2021-2024 | Monjuvi, Pemazyre |
| Deciphera Pharmaceuticals INC. | $171.33 | 2025 | Qinlock |
| Sobi, INC | $137.03 | 2022-2025 | |
| Stryker Corporation | $133.60 | 2023 | Xpress Ent Dilation System, 1788, Spy-Phi System |
| Rigel Pharmaceuticals, INC. | $124.99 | 2023 | Rezlidhia, Tavalisse |
| Puma Biotechnology, INC. | $124.95 | 2019 | |
| Amgen INC. | $108.09 | 2019-2023 | Xgeva, Nplate, Vectibix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $98.22 | 2023 | Da Vinci Surgical System |
| Pfizer INC. | $80.57 | 2023 | |
| Alexion Pharmaceuticals, INC. | $68.03 | 2022-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $52.36 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $52.26 | 2019-2020 | |
| Dova Pharmaceuticals | $47.21 | 2020 | |
| Iovance Biotherapeutics, INC. | $41.03 | 2024 | Amtagvi |
| Emd Serono, INC. | $32.81 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2021 | |
| Tempus Ai, INC | $27.07 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $23.23 | 2021 | |
| Springworks Therapeutics, INC. | $21.66 | 2024 | Ogsiveo |
| Daiichi Sankyo INC. | $17.72 | 2025 | Vanflyta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gino In listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.